Fulcrum Therapeutics, Inc. 8-K

What Happened
Fulcrum Therapeutics announced on April 23, 2026 that it provided written notice terminating the July 5, 2023 license agreement with CAMP4 Therapeutics covering CAMP4’s Diamond‑Blackfan anemia program; the termination will be effective in accordance with the license terms. On April 27, 2026 Fulcrum furnished a press release reporting its financial results for the quarter ended March 31, 2026 (Exhibit 99.1 to the 8‑K). The company’s CFO and treasurer, Alan Musso, notified Fulcrum on April 23, 2026 of his intent to retire; he will remain in his role until a successor is named and will provide consulting support through February 2027. Also on April 23, 2026 the Board appointed Josh Lehrer as an independent Class III director and member of the Science & Technology Committee.

Key Details

• Fulcrum gave CAMP4 written termination notice on April 23, 2026 for the July 5, 2023 license covering certain small molecules, patents and know‑how for the Diamond‑Blackfan anemia program.
• Under the original CAMP4 License Fulcrum made an undisclosed upfront, non‑refundable payment; CAMP4 stood to receive up to $35.0M in development/regulatory milestones, up to $35.0M in sales milestones and royalties if products were commercialized.
• Q1 2026 results were announced April 27, 2026; the related press release is furnished as Exhibit 99.1 (no financial line‑items were included in the 8‑K text).
• Governance and transition: Josh Lehrer appointed April 23, 2026 (one‑time option to buy 64,000 shares at $8.08 exercise price); CFO Alan Musso to remain in role during search, then consult through Feb 2027; Fulcrum extended post‑termination option exercise period by 12 months following his consulting period.

Why It Matters
The CAMP4 license termination removes Fulcrum’s rights to pursue CAMP4’s Diamond‑Blackfan anemia program under that agreement and eliminates the potential future milestone and royalty obligations and opportunities tied to that collaboration (up to $70M in milestone payments plus royalties if earned). Investors should review the April 27, 2026 press release (Exhibit 99.1) for the company’s reported quarterly financials and guidance. Leadership continuity is supported by Mr. Musso remaining through the transition and by the Board’s immediate appointment of an independent director; these steps reduce short‑term operational disruption while Fulcrum conducts an executive search.